PT3966206T - Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de utilização dos mesmos - Google Patents
Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de utilização dos mesmosInfo
- Publication number
- PT3966206T PT3966206T PT207283656T PT20728365T PT3966206T PT 3966206 T PT3966206 T PT 3966206T PT 207283656 T PT207283656 T PT 207283656T PT 20728365 T PT20728365 T PT 20728365T PT 3966206 T PT3966206 T PT 3966206T
- Authority
- PT
- Portugal
- Prior art keywords
- heteroarylaminopyrimidine
- amide
- methods
- autophagy inhibitors
- autophagy
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title 1
- 239000012822 autophagy inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962846264P | 2019-05-10 | 2019-05-10 | |
US201962846260P | 2019-05-10 | 2019-05-10 | |
US201962911736P | 2019-10-07 | 2019-10-07 | |
US201962911733P | 2019-10-07 | 2019-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3966206T true PT3966206T (pt) | 2023-11-10 |
Family
ID=70847594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT207283656T PT3966206T (pt) | 2019-05-10 | 2020-05-08 | Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de utilização dos mesmos |
Country Status (26)
Country | Link |
---|---|
US (2) | US11518758B2 (pt) |
EP (2) | EP3966206B1 (pt) |
JP (1) | JP2022531932A (pt) |
KR (1) | KR20220019696A (pt) |
CN (1) | CN114072397A (pt) |
AU (1) | AU2020274011B2 (pt) |
BR (1) | BR112021022576A2 (pt) |
CA (1) | CA3139120A1 (pt) |
CL (1) | CL2021002953A1 (pt) |
CO (1) | CO2021016765A2 (pt) |
DK (1) | DK3966206T3 (pt) |
ES (1) | ES2962852T3 (pt) |
FI (1) | FI3966206T3 (pt) |
HR (1) | HRP20231310T1 (pt) |
HU (1) | HUE064465T2 (pt) |
IL (1) | IL287795A (pt) |
LT (1) | LT3966206T (pt) |
MX (1) | MX2021013662A (pt) |
PE (1) | PE20220592A1 (pt) |
PL (1) | PL3966206T3 (pt) |
PT (1) | PT3966206T (pt) |
RS (1) | RS64755B1 (pt) |
SG (1) | SG11202112171XA (pt) |
SI (1) | SI3966206T1 (pt) |
TW (1) | TW202108574A (pt) |
WO (1) | WO2020231808A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3089566A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
HRP20231478T1 (hr) | 2018-12-28 | 2024-04-26 | Deciphera Pharmaceuticals, Llc | Csf1r inhibitori za primjenu u liječenju raka |
JP2022517222A (ja) | 2019-01-10 | 2022-03-07 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
RS64755B1 (sr) | 2019-05-10 | 2023-11-30 | Deciphera Pharmaceuticals Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primene |
US11530206B2 (en) | 2019-05-10 | 2022-12-20 | Deciphera Pharmaceuticals, Llc | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
KR20220024605A (ko) | 2019-06-17 | 2022-03-03 | 데시페라 파마슈티칼스, 엘엘씨. | 아미노피리미딘 아미드 자가포식 억제제 및 이의 사용 방법 |
CN114615982A (zh) | 2019-08-12 | 2022-06-10 | 德西费拉制药有限责任公司 | 用于治疗胃肠道间质瘤的瑞普替尼 |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
JP2022546043A (ja) | 2019-08-29 | 2022-11-02 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12d阻害剤 |
CA3152025A1 (en) | 2019-09-24 | 2021-04-01 | David BRIERE | Combination therapies |
EP4076418A4 (en) | 2019-12-20 | 2024-01-24 | Mirati Therapeutics Inc | SOS1 INHIBITORS |
LT4084778T (lt) | 2019-12-30 | 2024-01-25 | Deciphera Pharmaceuticals, Llc | Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai |
CN115243681A (zh) | 2019-12-30 | 2022-10-25 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
WO2022109001A1 (en) | 2020-11-18 | 2022-05-27 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
CN113527294A (zh) * | 2021-08-25 | 2021-10-22 | 都创(上海)医药开发有限公司 | Mrtx849化合物的晶型及其制备方法和用途 |
CN115894404A (zh) * | 2021-09-22 | 2023-04-04 | 杭州天玑济世生物科技有限公司 | 一类具有萘胺结构的小分子化合物及其应用 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
GB9910807D0 (en) | 1999-05-10 | 1999-07-07 | Prometic Biosciences Limited | Novel detoxification agents and their use |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
EP1282606B1 (en) | 2000-05-08 | 2015-04-22 | Janssen Pharmaceutica NV | Hiv replication inhibiting pyrimidines and triazines |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
AU2002316421B2 (en) | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
EP1438053B1 (de) | 2001-10-17 | 2008-09-10 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
JP4072615B2 (ja) | 2002-03-05 | 2008-04-09 | 独立行政法人産業技術総合研究所 | 配位子を有する複素環化合物及びその製造方法、及びこの複素環化合物を用いる金属元素の固定化膜 |
CN1717396A (zh) | 2002-11-28 | 2006-01-04 | 舍林股份公司 | Chk-、Pdk-和Akt-抑制嘧啶,其制备及作为药物的用途 |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
CL2004000306A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
CN100549014C (zh) | 2003-07-16 | 2009-10-14 | 詹森药业有限公司 | 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物 |
US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
JP4741491B2 (ja) | 2003-08-07 | 2011-08-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 抗増殖剤としての2,4−ピリミジンジアミン化合物および使用 |
WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
UA92150C2 (ru) | 2004-06-04 | 2010-10-11 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
CA2593463C (en) | 2005-01-07 | 2013-10-08 | F. Hoffmann-La Roche Ag | [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
JP5369257B2 (ja) | 2006-02-15 | 2013-12-18 | アッヴィ・インコーポレイテッド | 新規なアセチル−CoAカルボキシラーゼ(ACC)阻害薬およびそれらの糖尿病、肥満および代謝症候群での使用 |
BRPI0711628A2 (pt) | 2006-05-15 | 2011-12-06 | Irm Llc | composto, composição farmacêutica, uso e processo para preparação do composto |
US20070293494A1 (en) | 2006-06-15 | 2007-12-20 | Djung Jane F | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines |
US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
CN101611035A (zh) | 2006-12-28 | 2009-12-23 | 大正制药株式会社 | 吡唑并嘧啶化合物 |
US8143293B2 (en) | 2007-04-20 | 2012-03-27 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases |
JP2011500727A (ja) | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 |
US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
EP2303277A4 (en) | 2008-06-26 | 2011-08-17 | Glaxosmithkline Llc | HAMMER OF ACT ACTIVITY |
ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AU2009308853A1 (en) | 2008-10-29 | 2010-05-06 | Deciphera Pharmaceuticals, Llc | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
PE20121480A1 (es) | 2009-12-17 | 2012-11-10 | Merck Sharp & Dohme | Aminopirimidinas como inhibidores de syk |
SG181965A1 (en) | 2009-12-30 | 2012-08-30 | Avila Therapeutics Inc | Ligand-directed covalent modification of protein |
AU2011248441A1 (en) | 2010-04-29 | 2012-12-20 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
AU2011245248B2 (en) | 2010-04-29 | 2016-01-07 | Deciphera Pharmaceuticals, Llc | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites |
WO2012033195A1 (ja) | 2010-09-10 | 2012-03-15 | 京都薬品工業株式会社 | 複素環化合物 |
WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
AU2012288892B2 (en) * | 2011-07-28 | 2016-04-21 | Cellzome Limited | Heterocyclyl pyrimidine analogues as JAK inhibitors |
MX2014006126A (es) | 2011-11-22 | 2015-03-19 | Deciphera Pharmaceuticals Llc | Amidas de piridona y analogos que exhiben actividades anticancerigenas y antiproliferativas. |
CA2850705C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
JP6117816B2 (ja) | 2011-11-29 | 2017-04-19 | ジェネンテック, インコーポレイテッド | Lrrk2モジュレーターとしてのアミノピリミジン誘導体 |
CN104093426B (zh) | 2011-11-30 | 2019-06-28 | 健泰科生物技术公司 | 用于lrrk2的正电子发射体层摄影(pet)成像的氟-18和碳-11标记的放射性配体 |
WO2013134298A1 (en) | 2012-03-07 | 2013-09-12 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US20140073634A1 (en) | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
SG11201507660TA (en) | 2013-03-15 | 2015-10-29 | Deciphera Pharmaceuticals Llc | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145029A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145015A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145004A1 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145023A1 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
US9382228B2 (en) | 2013-03-15 | 2016-07-05 | Deciphera Pharmaceuticals, Llc | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用 |
CA2917667A1 (en) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
BR112016005881A2 (pt) | 2013-09-18 | 2017-09-12 | Beijing Hanmi Pharmaceutical Co Ltd | composto, composição farmacêutica e uso do composto |
CN104262328B (zh) | 2013-09-18 | 2016-09-07 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
MY184733A (en) | 2013-10-18 | 2021-04-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
SG11201602387RA (en) | 2013-10-21 | 2016-05-30 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
US20150284341A1 (en) | 2014-04-07 | 2015-10-08 | Catylix, Inc. | Fluoroalkyl-substituted derivatives of pyridine, pyrimidine, and pyrazine |
US10266549B2 (en) | 2014-08-25 | 2019-04-23 | Salk Institute For Biological Studies | ULK1 inhibitors and methods using same |
JP2018510140A (ja) | 2015-02-25 | 2018-04-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | アルキニルアルコール及び使用方法 |
US10336734B2 (en) | 2015-08-02 | 2019-07-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of ACK1/TNK2 tyrosine kinase |
US10738016B2 (en) | 2015-10-13 | 2020-08-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | BRD4-kinase inhibitors as cancer therapeutics |
US11028080B2 (en) * | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
CA3054809A1 (en) | 2017-02-28 | 2018-09-07 | The General Hospital Corporation | Uses of pyrimidopyrimidinones as sik inhibitors |
US20200129489A1 (en) | 2017-05-30 | 2020-04-30 | Deciphera Pharmaceuticals, Llc | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
CN109535132B (zh) * | 2017-09-21 | 2021-07-20 | 北京赛特明强医药科技有限公司 | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 |
KR20200115606A (ko) | 2018-01-31 | 2020-10-07 | 데시페라 파마슈티칼스, 엘엘씨. | 비만 세포증의 치료를 위한 병용 요법 |
KR20200143709A (ko) | 2018-04-10 | 2020-12-24 | 뉴로포레 테라피스, 인코포레이티드 | Pi3-키나제 및 오토파지 경로의 조절인자로서의 트리-치환된 아릴 및 헤테로아릴 유도체 |
HRP20231478T1 (hr) | 2018-12-28 | 2024-04-26 | Deciphera Pharmaceuticals, Llc | Csf1r inhibitori za primjenu u liječenju raka |
US11530206B2 (en) | 2019-05-10 | 2022-12-20 | Deciphera Pharmaceuticals, Llc | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
RS64755B1 (sr) | 2019-05-10 | 2023-11-30 | Deciphera Pharmaceuticals Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primene |
KR20220024605A (ko) | 2019-06-17 | 2022-03-03 | 데시페라 파마슈티칼스, 엘엘씨. | 아미노피리미딘 아미드 자가포식 억제제 및 이의 사용 방법 |
-
2020
- 2020-05-08 RS RS20230959A patent/RS64755B1/sr unknown
- 2020-05-08 TW TW109115472A patent/TW202108574A/zh unknown
- 2020-05-08 PT PT207283656T patent/PT3966206T/pt unknown
- 2020-05-08 CA CA3139120A patent/CA3139120A1/en active Pending
- 2020-05-08 SG SG11202112171XA patent/SG11202112171XA/en unknown
- 2020-05-08 FI FIEP20728365.6T patent/FI3966206T3/fi active
- 2020-05-08 CN CN202080049743.1A patent/CN114072397A/zh active Pending
- 2020-05-08 HU HUE20728365A patent/HUE064465T2/hu unknown
- 2020-05-08 PE PE2021001871A patent/PE20220592A1/es unknown
- 2020-05-08 LT LTEPPCT/US2020/032090T patent/LT3966206T/lt unknown
- 2020-05-08 BR BR112021022576A patent/BR112021022576A2/pt unknown
- 2020-05-08 EP EP20728365.6A patent/EP3966206B1/en active Active
- 2020-05-08 EP EP23190061.4A patent/EP4295846A3/en active Pending
- 2020-05-08 HR HRP20231310TT patent/HRP20231310T1/hr unknown
- 2020-05-08 ES ES20728365T patent/ES2962852T3/es active Active
- 2020-05-08 PL PL20728365.6T patent/PL3966206T3/pl unknown
- 2020-05-08 AU AU2020274011A patent/AU2020274011B2/en active Active
- 2020-05-08 KR KR1020217040561A patent/KR20220019696A/ko unknown
- 2020-05-08 MX MX2021013662A patent/MX2021013662A/es unknown
- 2020-05-08 SI SI202030293T patent/SI3966206T1/sl unknown
- 2020-05-08 US US16/870,418 patent/US11518758B2/en active Active
- 2020-05-08 WO PCT/US2020/032090 patent/WO2020231808A1/en active Application Filing
- 2020-05-08 JP JP2021566466A patent/JP2022531932A/ja active Pending
- 2020-05-08 DK DK20728365.6T patent/DK3966206T3/da active
-
2021
- 2021-11-02 IL IL287795A patent/IL287795A/en unknown
- 2021-11-09 CL CL2021002953A patent/CL2021002953A1/es unknown
- 2021-12-10 CO CONC2021/0016765A patent/CO2021016765A2/es unknown
-
2022
- 2022-06-03 US US17/832,224 patent/US20230047915A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202112171XA (en) | 2021-12-30 |
CN114072397A (zh) | 2022-02-18 |
CO2021016765A2 (es) | 2022-04-08 |
EP4295846A3 (en) | 2024-02-28 |
CA3139120A1 (en) | 2020-11-19 |
TW202108574A (zh) | 2021-03-01 |
HUE064465T2 (hu) | 2024-04-28 |
IL287795A (en) | 2022-01-01 |
SI3966206T1 (sl) | 2023-12-29 |
EP3966206A1 (en) | 2022-03-16 |
US11518758B2 (en) | 2022-12-06 |
ES2962852T3 (es) | 2024-03-21 |
KR20220019696A (ko) | 2022-02-17 |
PL3966206T3 (pl) | 2024-01-29 |
JP2022531932A (ja) | 2022-07-12 |
US20230047915A1 (en) | 2023-02-16 |
DK3966206T3 (da) | 2023-11-13 |
FI3966206T3 (fi) | 2023-10-20 |
HRP20231310T1 (hr) | 2024-02-02 |
WO2020231808A1 (en) | 2020-11-19 |
CL2021002953A1 (es) | 2022-07-15 |
LT3966206T (lt) | 2023-11-10 |
PE20220592A1 (es) | 2022-04-22 |
RS64755B1 (sr) | 2023-11-30 |
BR112021022576A2 (pt) | 2022-01-25 |
US20200354346A1 (en) | 2020-11-12 |
MX2021013662A (es) | 2022-03-11 |
EP3966206B1 (en) | 2023-08-09 |
AU2020274011A1 (en) | 2021-11-25 |
EP4295846A2 (en) | 2023-12-27 |
AU2020274011B2 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287787A (en) | Phenylaminopyrimidine amide as autophagy inhibitors and methods of using them | |
IL287795A (en) | Heteroarylaminopyrimidine amide as autophagy inhibitors and methods of using them | |
IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
IL287751A (en) | kcnt1 inhibitors and methods of use | |
IL287768A (en) | kcnt1 inhibitors and methods of use | |
IL287973A (en) | acss2 inhibitors and methods of their use | |
IL288996A (en) | Aminopyrimidine amide autophagy inhibitors and methods of using them | |
IL276711A (en) | Arginase inhibitors and methods of using them | |
IL284640A (en) | PCSK9 inhibitors and methods of using them | |
IL284661A (en) | pcsk9 inhibitors and methods of using them | |
EP3986894A4 (en) | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | |
EP3846808A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
IL280924A (en) | Arginase inhibitors and methods of using them | |
EP3959197A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
IL264854A (en) | Spt5 inhibitors and methods of use thereof | |
IL286149A (en) | Caspase inhibitors and methods of using them | |
IL285108A (en) | Arginase inhibitors and methods of using them | |
EP4077332A4 (en) | LIN28 INHIBITORS AND THEIR METHODS OF USE |